AVTX - Avalo Therapeutics, Inc. Accounting Value per Share

Symbol and logo of brand Avalo Therapeutics, Inc (AVTX)

The market trend for Avalo Therapeutics, Inc (AVTX) on the GURU.Markets platform, as seen on this price chart, stands at 8.54. Avalo Therapeutics, Inc develops specific antibodies to combat severe inflammation, relying on patent protection and FDA approval. The business leverages partnerships with universities to discover new treatment pathways for immune pathologies. The project targets a massive market characterized by a shortage of effective medications.

AVTX Avalo Therapeutics, Inc. Share Book Value (07/04/2022 - 10/29/2026)

Summary analytical data breakdowns for avalotx.com (AVTX)

- share price and expert price forecast:
Stock Quotes Avalo Therapeutics Inc.|AVTX - Analyst Forecast Prices
- market capitalization statistics:
Market Valuation Avalo Therapeutics, Inc.|AVTX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Avalo Therapeutics|AVTX - Net Asset Value|Market Capitalization to Book Value Ratio avalotx.com|AVTX - Aggregate Asset Value
- debt burden and liquidity indicators:
Total Debt to Capital Avalo Therapeutics, Inc|AVTX - Long-Term Debt to Capital|Short-Term Debt to Equity Avalo Therapeutics|AVTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Avalo Therapeutics, Inc.|AVTX - Company Long-Term Liabilities|Company Short-Term Debts Avalo Therapeutics
General company analysis:AVTX - Avalo Therapeutics Inc.
Manufactured products of Avalo Therapeutics

Book value per share reflects the company's net assets minus liabilities, demonstrating the efficiency of capital management and profit reinvestment. By analyzing the book value per share under RAS, an investor assesses the ability of Avalo Therapeutics, Inc (AVTX) to capitalize on targeted antibody developments, where growth in this metric confirms the establishment of a foundation for a future patent monopoly in the systemic inflammation treatment sector.

Competitor analysis

ARGX: Accounting Value per Share|BioNTech Pharma - Book Price of a Share|ABVX (Abivax Corp) - Accounting Value per Share|Equity per Share ADMA|Net Assets per Single Share Protagonist|Immunovant Inc - Share Book Value|Book Value per Share KNSA|GRFS (Grifols Biemat) - Accounting Value of a Share|Book Value per Share ADPT (Adaptive Biotechnologies)|Book Value per Share celldex.com CLDX|AUPH - Net Assets per Single Share|Accounting Value of a Share BCRX (BioCryst Pharmaceuticals, Inc.)|Vera Pharma (VERA) - Net Assets per Single Share|Accounting Value per Share Dianthus Corp|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp|Accounting Value per Share TRML (Tourmaline Bio)|PGEN (Precigen Inc) - Accounting Value of a Share|Book Value per Share PHAR (Pharming)|Net Assets per Share Nektar Corp (NKTR)|UPB - Net Assets per Single Share|zenasbio.com (ZBIO) - Accounting Value per Share|Immunome (IMNM) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|Accounting Value per Share KALV|Book Value per Share Septerna Pharma|Net Assets per Single Share Pieris Pharmaceuticals (PVLA)|savarapharma.com - Equity per Share|Book Value per Share RIGL (Rigel Pharmaceuticals, Inc.)|AnaptysBio Inc (ANAB) - Net Asset Value per Share|Astria Pharma - Book Value per Share|ENGN - Book Value per Share|RAPT (RAPT Therapeutics, Inc.) - Accounting Value per Share|JBIO (Aerovate Therapeutics) - Net Assets per Single Share|ACRS (Aclaris Therapeutics, Inc.) - Book Value per Share|Book Value per Share Kyverna Therapeutics Inc.|Net Assets per Single Share Tiziana Life Sciences PLC (TLSA)|Net Assets per Single Share CABA (Cabaletta Bio Inc)|Net Assets per Single Share Ventyx Biosciences VTYX|theratech.com (THTX) - Net Asset Value per Share|ELDN: Accounting Value per Share|Accounting Value of a Share AGEN (Agenus, Inc.)|CLYM (Climb Bio, Inc.) - Accounting Value per Share|ZURA: Book Price of a Share|ATYR (aTyr Pharma, Inc.) - Book Value per Share|ADAG: Accounting Value of a Share|Book Value per Share IMA|STTK - Net Asset Value per Share|Net Assets per Single Share Equillium EQ|Accounting Value of a Share CNTB|Immunic Inc - Book Value per Share|ATRA - Book Value per Share|inflarx.de (IFRX) - Net Assets per Single Share|Share Book Value XFOR (X4 Pharmaceuticals Inc.)|ACET (Adicet Bio Inc.) - Book Value per Share|Net Asset Value per Share Celularity Corp CELU|Accounting Value per Share INMB (INmune Bio, Inc.)|Book Value per Share barinthusbio.com (BRNS)|Kezar Life Sciences, Inc. - Accounting Value per Share|Book Price of a Share SABS (SAB Biotherapeutics Inc.)|Akari Therapeutics plc - Book Value per Share|Net Assets per Share Enlivex Therapeutics ENLV|QTTB: Book Value per Share|Accounting Value per Share geovax.com|Net Assets per Single Share Edesa Biotech|iBio Inc (IBIO) - Net Assets per Share|Accounting Value per Share CARM (Carisma Therapeutics)|XTLB (XTL Bio) - Accounting Value of a Share|Book Value per Share BOLT (Bolt Biotherapeutics, Inc.)|Net Assets per Share HCW Biologics, Inc. (HCWB)|APVO - Net Assets per Single Share|AIM (AIM ImmunoTech, Inc.) - Equity per Share|ADTX: Book Value per Share|Accounting Value per Share GRI Bio Corporation|XRTX (XORTX Therapeutics Inc.) - Book Value per Share|Book Value per Share reshapelifesciences.com|Accounting Value per Share REVB (Revelation Biosciences, Inc.)|Net Assets per Single Share INDP (Indaptus Therapeutics Inc)|Scinai - Accounting Value per Share|Book Price of a Share CALI (CalciMedica Inc)|AFMD: Accounting Value per Share|ALLK (Allakos Inc.) - Equity per Share|hookipapharma.com (HOOK) - Net Assets per Single Share|Share Book Value IGMS (IGM Biosciences)|ITOS (iTeos) - Book Value per Share|OCEA: Accounting Value of a Share|Book Value per Share TCBP|Book Value per Share thirdharmonicbio.com (THRD)